Drug Trial Radar · NCT02105610
Volatile Anesthetics to Reduce Mortality in Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,400
Actual
Start
Apr 14, 2014
Primary completion
Oct 2017
Study completion Sep 2018
Sponsor
- Lead sponsor
- Università Vita-Salute San RaffaeleAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is initial evidence that the choice of anesthesia can influence survival in the specific setting of coronary artery bypass grafting surgery (CABG). A recent international consensus conference included volatile agents among the few drugs/techniques/strategies that might reduce perioperative mortality in cardiac surgery and that should be further studied. Volatile anesthetics (desflurane, isoflurane and sevoflurane) have non-anesthetic pharmacological characteristics that confer cardiac protection when compared to Total IntraVenous Anesthesia (TIVA). Several randomized controlled studies were summarized in a meta-analysis that documented a reduction in perioperative cardiac troponin release and mortality in patients receiving volatile anesthetics when compared to patients receiving a TIVA. There are four published studies (Bignami et al. 2009) (De Hert et al. 2009) (Jackobsen et al. 2007) (Landoni et al. 2007) suggesting that these benefits can translate into a reduced mortality rate in patients receiving volatile agents. The level of evidence for these four studies is not high (one meta-regression, one underpowered randomized controlled study, one retrospective study and one meta-analysis of small randomized studies) and there is need for a large multicentre randomized controlled study to confirm these findings, as suggested by the international consensus conference on this topic published in 2011 (Landoni et al 2011). The purpose is to provide a large multicentre controlled randomized trial to demonstrate that volatile anesthetics can reduce 1 year mortality from 3% to 2% in patients undergoing CABG (either with or without cardiopulmonary bypass). The results of this study can support the use of volatile agents in all CABG procedures worldwide (more than 500.000 per year) with 2.500 lives saved per year (in the hypothesis that nowadays half the procedures are performed with a TIVA and that 1 year mortality can be reduced from 3% to 2% using volatile agents).
Conditions
- Aortocoronary Bypass
- Cardiac Surgery
- Coronary Artery Bypass Grafting
Interventions
desflurane, isoflurane, sevofluraneDrug
total intravenous anestheticsDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- mortalityTime frame: 1 year
Locations
36 sites in 13 countries. Site status is shown where the registry gives one.
Mohammed Bin Khalifa Bin Sulman Al-Khalifa Cardiac Center - Bahrain
Bahrein, Bahrain
Dante Pazzanese Institute of Cardiology
São Paulo, Brazil
Hospital das Clínicas da Faculdade de Medicina da USP - Istituto do Coracao
São Paulo, Barazil, Brazil
Heart Center Pontica
Burgas, Bulgaria
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
The Second Xiangya Hospital of Central South University
Changsha, China
Wuhan Asia Heart Hospital
Hubei, China
1st Affiliated Hospital of Fourth Military University
Xi'an, China
University Hospital Dubrava
Dubrava, Croatia
General University Hospital, Charles University
Prague, Czech Republic, Czechia
Institute for Clinical and Experimental Medicine
Prague, Czech Republic, Czechia
Faculty of Medicine - Zagazig University
Zagazig, Egypt
Mansoura University hospitals
Egypt, Egypt, Egypt
Policlinico San Orsola-Malpighi
Bologna, Italy
Spedali Civili
Brescia, Italy
Policlinico Universitario Magna Graecia
Catanzaro, Italy
Ospedale San Raffaele di Milano, Italy
Milan, Italy
Humanitas
Milan, Italy
Azienda Ospedaliera di Padova
Padova, Italy
Azienda Ospedaliera San Camillo-Forlanini
Roma, Italy
Policlinico Universitario Campus Biomedico
Roma, Italy
AOU Città della Salute e della Scienza
Torino, Italy
Hospital Pulau Pinang
George Town, Malaysia, Malaysia
Hospital Serdang
Lumpur, Malaysia, Malaysia
University Malaya Medical Centre
Lumpur, Malaysia, Malaysia
Sarawak General Hospital
Sarawak, Malaysia, Malaysia
Hospital Santa Maria
Lisbon, Portugal
Federal Centre for Cardiac Surgery
Astrakhan, Russia
Scientific Research Institute for Complex Issues of Cardiovascular Disease
Kemerovo, Russia
Moscow Clinical Regional Research Institute
Moscow, Russia
Negovskiy Reanimatology Research Institute
Moscow, Russia
State Research Institute of Circulation Pathology
Novosibirsk, Russia
Federal Almazov Medical Research Centre
Saint Petersburg, Russia
Ural Institute of Cardiology
Yekaterinburg, Russia
King Abdullah Medical City - KAMC
Mecca, Saudi Arabia
Institute of Cardiovascular Diseases "Dedinje"
Belgrade, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.